How to choose several new crown vaccines in my country in the future? Is there any advantage to double injection? Expert response

News 1+1丨How does Chinese vaccine play a role in the world?

　　The interim analysis of the vaccine jointly developed by Academician Chen Wei and Cansino Biologicals showed that 28 days after a single injection of the vaccine, the vaccine’s protective efficiency against severe new coronary pneumonia was 100%, and the overall protection efficiency was 74.8%. Nothing happened. Serious adverse reactions related to the vaccine.

What does it mean to be the first vaccine to enter clinical trials in China?

"News 1+1" Bai Yansong connected with Shao Yiming, a researcher at the China Centers for Disease Control and Prevention, and a consultant for the WHO Vaccine R&D Committee, for common concern.

Is there any advantage to double injection?

　　The vaccine of Academician Chen Wei's team is a single shot, which has huge advantages.

So does double injection vaccination have other advantages?

　　Shao Yiming, a researcher at the Chinese Center for Disease Control and Prevention and a consultant to the WHO Vaccine R&D Committee: Everything has disadvantages and advantages. Although double-dose vaccination has a longer immunization cycle, it may ensure that the two-dose vaccination rate will decrease, but the intensity of the immune response it induces , Can predict its future durability, so it has its own advantages and disadvantages.

Is Chen Wei's team vaccine progress "slow"?

　　The vaccine developed by Academician Chen Wei’s team was the first to enter people’s sight and clinical trials were also the first to begin.

But when I heard the news today, the first reaction of many people would be that Sinopharm and Kexing have been vaccinated for so long. Why is the vaccine of Academician Chen Wei "slow"?

　　Shao Yiming, a researcher at the Chinese Center for Disease Control and Prevention and a consultant to the WHO Vaccine Research and Development Committee: After the outbreak of the new crown, not only in our country, but global vaccines are advancing at an ultra-fast speed.

So the so-called "slow" is mainly because the domestic epidemic is well controlled. We can only conduct Phase I and Phase II clinical trials in people who are not at risk and there is no virus attack in the country.

But by the third phase, there must be a high rate of new infections and a large number of cases in order to test the protective effect of the vaccine against the disease.

We no longer have this condition in our country, and can only carry out Phase III clinical trials overseas.

This depends on the countries we cooperate with, as well as the cooperative institutions, the efficiency between them and the conditions between them, so some countries may not have the highest incidence rates, such as Europe and the United States, where the incidence rate is particularly high, and the progress can be rapid.

So in this case we are limited by people.

How to choose several new crown vaccines in my country in the future?

　　Many countries do not have a vaccine and need to import a large amount. There are already several vaccines in my country, so how to choose?

　　Shao Yiming, a researcher at the Chinese Center for Disease Control and Prevention and an adviser to the WHO Vaccine R&D Committee: This issue is very important. It is not only related to national decision-making departments, but also related to the public's participation in vaccine vaccination. It is a very critical issue.

Although my country has five technical routes, each vaccine is different in terms of effectiveness, safety, and accessibility.

From the point of view of protection effect, the protection effect of the latest mRNA vaccine is more than 90%, and that of inactivated vaccines and viral vector vaccines is in the range of 70% to 80%.

In terms of safety, medicine is an experimental science. Only through experiments, its safety and power depend on how many people have been tested and how long it has been for.

Inactivated vaccines have been used by humans for hundreds of years, and the entire earth has used them, so its safety and confidence in it are the highest.

　　How accessible is China's vaccine storage and transportation?

　　The storage and transportation environment of several vaccines in China is 2-8 degrees above zero, but the effective rate in the United States is more than 90%. It requires 60 to 70 degrees below zero, which most countries cannot do.

And China chose to be pragmatic at the beginning of vaccine research and development, which is also considering for developing countries.

　　Shao Yiming, a researcher at the Chinese Center for Disease Control and Prevention and a consultant to the WHO Vaccine R&D Committee: In terms of the availability of vaccines in my country, the storage and transportation environments are both at 2-8 degrees, and many of our companies have done accelerated tests, even if stored at 37 degrees. There is no problem in weeks, so during transportation, even if the transportation conditions are worse, our vaccine can guarantee the quality and effect.

In this sense, those temperature conditions that require minus 70 degrees or minus 20 degrees to 30 degrees are not suitable for use in developing countries. Even in developed countries with backward economic conditions, it is difficult to scale up Crowd vaccination.

In addition, the reason why the availability of vaccines in my country has received so many developing countries’ attention in the world is that in addition to the scientific and technological resilience of the vaccine itself, it is also related to the construction of a community with a shared future for mankind in my country and the idea that vaccines in China are public products. The support for developing countries is basically synchronized with our country’s philosophy.